The treatment was already approved for pediatric upper limb spasticity earlier this year. This new approval was based on data from a phase 3 trial evaluating the safety and efficacy of Botox in 381 ...
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport® (abobotulinumtoxinA) in Pediatric Lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback